Phase I trial of novel CAR-T cell therapy for pediatric midline gliomas | 2 Minute Medicine
2 Minute Medicine ,
1. Approximately 88% of patients with GD2-positive diffuse midline glioma or other progressive CNS tumours receiving C7R-GD2.CART…
1. Approximately 88% of patients with GD2-positive diffuse midline glioma or other progressive CNS tumours receiving C7R-GD2.CART…
Novel therapeutic approaches are needed for children with diffuse midline glioma (DMG) and other recurrent high-grade central…
Novel therapeutic approaches are needed for children with diffuse midline glioma (DMG) and other recurrent high-grade central…